Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPIVITE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Major depressive disorder,Generalized anxiety disorder,Panic disorder,Obsessive-compulsive disorder,Social anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder,Bulimia nervosa
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
250 mg orally twice daily
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min)
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hepatic via CYP2D6, CYP2C9, CYP3A4, and CYP2C19; major active metabolite: norfluoxetine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
98% bound to albumin and alpha-1-acid glycoprotein
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd 0.25 L/kg (0.18-0.33 L/kg); indicates predominantly extracellular distribution
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 75% (range 60-85%); food decreases bioavailability by 20%
70-90% (oral); 100% (IV).
GFR >= 60 m L/min: no adjustment. GFR 30-59 m L/min: 1.2 mg/kg IV every 12 hours. GFR 15-29 m L/min: 0.8 mg/kg IV every 12 hours. GFR < 15 m L/min: 0.5 mg/kg IV every 12 hours.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: 1.2 mg/kg IV every 12 hours. Child-Pugh C: 0.9 mg/kg IV every 12 hours.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
2 mg/kg IV every 12 hours for children 1-12 years; maximum single dose 100 mg. For infants 1-12 months: 2.5 mg/kg every 12 hours.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lowest adult dose; consider 1.2 mg/kg IV every 12 hours if Cr Cl >= 60 m L/min. Monitor renal function closely; reduce dose per renal adjustment if Cr Cl < 60 m L/min.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Serotonin syndrome; bleeding risk; activation of mania/hypomania; hyponatremia; QT prolongation; weight loss in children; sexual dysfunction; withdrawal reactions; drug interactions with MAOIs, other serotonergics.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Concurrent use with MAOIs or within 14 days of MAOI therapy; known hypersensitivity to fluoxetine; use with pimozide or thioridazine due to QT prolongation risk.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-protein meals with enzyme as they may reduce effectiveness. Do not take with acidic foods (e.g., citrus, vinegar) which may degrade the enzyme. Alcohol may increase GI side effects.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and premature closure of ductus arteriosus. Avoid in pregnancy.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Contraindicated in breastfeeding. M/P ratio not established; potential for infant toxicity due to accumulation in breast milk.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No safe dose in pregnancy. If inadvertent exposure, discontinue immediately and provide supportive care. Pharmacokinetic changes in pregnancy increase clearance by 30-40%, but contraindication overrides any dose adjustment.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
SERPIVITE (serrapeptase) is a proteolytic enzyme used for its anti-inflammatory and mucolytic effects. It is not a standard pharmaceutical; verify regulatory status. Monitor for bleeding risk when used with anticoagulants. Onset of action may be delayed; not for acute conditions. Use with caution in peptic ulcer disease.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take on an empty stomach at least 30 minutes before or 2 hours after meals.,Do not crush or chew enteric-coated tablets; swallow whole.,Report signs of bleeding (easy bruising, nosebleeds, blood in stool).,Avoid use if allergic to enzymes or if you have a bleeding disorder.,Consult healthcare provider before use if pregnant, breastfeeding, or on anticoagulants.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPIVITE vs ALDOCLOR-250, answered by our medical review team.
SERPIVITE is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPIVITE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPIVITE is: 1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPIVITE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPIVITE is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of neural tube defects, cardiac anomalies, and cleft palate due to folate antagonism. Second and third trimesters: Risk of feta. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.